Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
| Autor: | Toshikuni Suda, Ryosaku Shirahashi, Masaya Tamano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
direct-acting antiviral agents hypozincemia Serum albumin chemistry.chemical_element Zinc Hepacivirus 030204 cardiovascular system & hematology Gastroenterology Antiviral Agents 03 medical and health sciences 0302 clinical medicine Chronic hepatitis Internal medicine Internal Medicine Medicine Sustained viral response Humans University medical biology business.industry General Medicine Hepatitis C Hepatitis C Chronic medicine.disease chemistry biology.protein Zinc deficiency 030211 gastroenterology & hepatology Original Article hepatitis C business Direct acting |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | Objective Hypozincemia is a decrease in the serum zinc level of patients with hepatitis C and often requires zinc supplementation to improve the hepatic function. Our previous study showed the efficacy of direct-acting antiviral agent (DAA) treatment on serum zinc levels in patients with hepatitis C without zinc supplementation. In this study, we aimed to prospectively examine factors related to the improvement of serum zinc levels of patents with hepatitis C with DAA treatment. Methods Fifty-three patients with hepatitis C treated with DAAs between March 2018 and February 2019 at a university medical center were divided into two groups based on their initial serum level: the zinc deficiency group (n=43 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|